Skip to main
ELAN
ELAN logo

ELAN Stock Forecast & Price Target

ELAN Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 43%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Elanco Animal Health has demonstrated strong market leadership through its flagship product, Simparica Trio, which holds over 50% market share, while its product Credelio Quattro is projected to improve its market position to 16.8% by 2026, signaling robust growth potential. Additionally, notable year-over-year growth for other product lines, such as the Advantage Family and Seresto, at +33% and +28% respectively for the third quarter of 2025, indicates a solid upward trend in performance. These factors collectively contribute to a favorable outlook for Elanco's stock as the company continues to expand its presence and market share in the animal health sector.

Bears say

Elanco Animal Health's financial outlook appears negative due to concerns regarding its refinancing risks, as highlighted by Dentsply Sirona's recent high-interest offering, which could impact earnings growth in 2026. Despite a significant revenue increase of approximately 50%, the company's EBITDA margin has declined by a few hundred basis points, indicating potential challenges in cost management and profitability. Furthermore, while there was a reported EBITDA outperformance of $28 million in Q2, this may not be sufficient to mitigate ongoing concerns about future earnings and overall financial health.

ELAN has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 43% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elanco Animal Health Inc (ELAN) Forecast

Analysts have given ELAN a Buy based on their latest research and market trends.

According to 7 analysts, ELAN has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elanco Animal Health Inc (ELAN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.